Send to

Choose Destination
Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5.

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

Author information

Division of Infection and Immunity, UCL, London, UK.
Department of Infection, UCLH, London, UK.
Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Africa Health Research Institute, Durban, South Africa.
Division of Infection and Immunity, UCL, London, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
IrsiCaixa AIDS Research Institute, Badalona, Spain.
University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain.
Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Translational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands.
Department of Haematology, University of Cambridge, Cambridge, UK.
Department of Virology, UCLH, London, UK.
Department of Haematology, UCLH, London, UK.
Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Imperial College London, London, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK.
Department of Medicine, National University of Singapore, Singapore, Singapore.
Department of Haematology, Chelsea and Westminster Hospitals Foundation NHS Trust, London, UK.


A cure for HIV-1 remains unattainable as only one case has been reported, a decade ago1,2. The individual-who is known as the 'Berlin patient'-underwent two allogeneic haematopoietic stem-cell transplantation (HSCT) procedures using a donor with a homozygous mutation in the HIV coreceptor CCR5 (CCR5Δ32/Δ32) to treat his acute myeloid leukaemia. Total body irradiation was given with each HSCT. Notably, it is unclear which treatment or patient parameters contributed to this case of long-term HIV remission. Here we show that HIV-1 remission may be possible with a less aggressive and toxic approach. An adult infected with HIV-1 underwent allogeneic HSCT for Hodgkin's lymphoma using cells from a CCR5Δ32/Δ32 donor. He experienced mild gut graft-versus-host disease. Antiretroviral therapy was interrupted 16 months after transplantation. HIV-1 remission has been maintained over a further 18 months. Plasma HIV-1 RNA has been undetectable at less than one copy per millilitre along with undetectable HIV-1 DNA in peripheral CD4 T lymphocytes. Quantitative viral outgrowth assays from peripheral CD4 T lymphocytes show no reactivatable virus using a total of 24 million resting CD4 T cells. CCR5-tropic, but not CXCR4-tropic, viruses were identified in HIV-1 DNA from CD4 T cells of the patient before the transplant. CD4 T cells isolated from peripheral blood after transplantation did not express CCR5 and were susceptible only to CXCR4-tropic virus ex vivo. HIV-1 Gag-specific CD4 and CD8 T cell responses were lost after transplantation, whereas cytomegalovirus-specific responses were detectable. Similarly, HIV-1-specific antibodies and avidities fell to levels comparable to those in the Berlin patient following transplantation. Although at 18 months after the interruption of treatment it is premature to conclude that this patient has been cured, these data suggest that a single allogeneic HSCT with homozygous CCR5Δ32 donor cells may be sufficient to achieve HIV-1 remission with reduced intensity conditioning and no irradiation, and the findings provide further support for the development of HIV-1 remission strategies based on preventing CCR5 expression.


Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center